Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) EBIAT: 2010-2018

Historic EBIAT for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$33.1 million.

  • EyePoint Pharmaceuticals' EBIAT fell 453.67% to -$33.1 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$80.3 million, marking a year-over-year decrease of 364.08%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
  • As of Q3 2018, EyePoint Pharmaceuticals' EBIAT stood at -$33.1 million, which was up 3.78% from -$34.4 million recorded in Q2 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' EBIAT peaked at $20.6 million during Q3 2014, and registered a low of -$34.4 million during Q2 2018.
  • Over the past 3 years, EyePoint Pharmaceuticals' median EBIAT value was -$6.1 million (recorded in 2017), while the average stood at -$10.6 million.
  • Its EBIAT has fluctuated over the past 5 years, first spiked by 657.80% in 2014, then slumped by 8,529.85% in 2017.
  • Over the past 5 years, EyePoint Pharmaceuticals' EBIAT (Quarterly) stood at -$4.1 million in 2014, then declined by 27.26% to -$5.2 million in 2015, then soared by 98.71% to -$67,000 in 2016, then plummeted by 8,529.85% to -$5.8 million in 2017, then slumped by 453.67% to -$33.1 million in 2018.
  • Its EBIAT was -$33.1 million in Q3 2018, compared to -$34.4 million in Q2 2018 and -$7.0 million in Q1 2018.